Too Many Drugs, Too Little Value in CV Conditions
With the potential to treat multiple indications, a flood of cardiovascular drugs with purportedly novel mechanisms of action are expected to hit the market within 24 months. But because of the rapid progress in treating heart disease, what was novel years ago now appears mundane, diminishing the value of scientific breakthroughs that used to assure success.
You may also be interested in...
Results of two recent studies reported at this year's American Heart Association meeting favor devices over therapeutics in treating certain cardiovascular conditions. The PRESTO trial results were the equivalent of a dodged bullet for stent companies; it showed no benefit from the drug Tranilast, a result which leaves intact the supposition that drug-eluting stents are the best restenosis treatment. And another major trial found that implantable LVADs have superior results in treatment patients with chronic end-stage heart failure.
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.